The global Drug Eluting Balloon (DEB) Market is projected to grow from US$ 1.9 billion in 2024 to US$ 3.2 billion by 2034, at a steady CAGR of 5.4%. In 2024, North America held the largest market share at 36.7%, contributing approximately US$ 0.7 billion in revenue. This growth is closely tied to the rising burden of cardiovascular diseases (CVDs) worldwide. As per the World Health Organization (WHO), CVDs remain the leading cause of death globally, accounting for 17.9 million deaths annually. Drug eluting balloons are widely used in treating coronary and peripheral artery diseases, especially in patients where conventional stents may not be suitable.

In addition to aging, the rising prevalence of diabetes and obesity is boosting market demand. The Centers for Disease Control and Prevention (CDC) states that 11.6% of the U.S. population is diabetic. Diabetes significantly raises the risk of peripheral artery disease (PAD), a condition that often requires intervention with DEBs. As global diabetes cases continue to increase, the need for advanced vascular treatment options is also rising, especially in high-risk patient groups.

Government healthcare initiatives and growing public investment in cardiovascular infrastructure are further accelerating the market. Efforts by public health agencies like the European Society of Cardiology and organizations in Asia and North America are driving early diagnosis and improved access to treatment. These programs are helping to educate both patients and physicians on the benefits of DEBs, particularly in developing countries with rising heart disease rates.

Key Takeaways

• In 2024, the global Drug Eluting Balloon market generated approximately US$ 1.9 billion in revenue, with projections reaching US$ 3.2 billion by 2034.
• The market is growing steadily at a compound annual growth rate (CAGR) of 5.4% throughout the 2025 to 2034 forecast period.
• The product category includes peripheral, coronary, and other types of drug eluting balloons used in treating vascular and cardiac conditions.
• Peripheral drug eluting balloons dominated the market in 2023, securing a strong 50.4% share among all product type segments.
• In terms of technology, Paccocath emerged as the front-runner, holding a significant 56.3% share in the global market.
• Other key DEB technologies include Enduracoat, Freepac, Transpax, and several emerging alternatives still gaining traction.
• When looking at end users, hospitals and ambulatory surgery centers led with the largest revenue share of 59.2%.
• CATH laboratories and other healthcare facilities also contribute notably, though they trail behind hospitals in overall market contribution.

GET SAMPLE REPORT : https://market.us/report/global-drug-eluting-balloon-market/request-sample/

Emerging Trends

1. Growing Use in Peripheral Artery Disease (PAD)

The use of drug eluting balloons is increasing, especially for treating peripheral artery disease (PAD). This condition affects blood flow in the legs. Doctors are now choosing DEBs more often because they release medication straight into the artery walls. This helps lower the risk of the artery narrowing again. DEBs provide good results without leaving anything permanent behind, unlike stents. Patients also benefit from faster recovery times. Hospitals and clinics are adopting this method more widely. As PAD cases continue to rise, especially among older adults, DEBs are becoming a key option in vascular care.

2. Shift Toward Minimally Invasive Procedures

Healthcare systems are moving away from open surgeries. There’s a strong shift toward minimally invasive treatments. DEBs play an important role in this trend. Unlike stents, they do not require implanting a device. This makes the procedure safer and simpler. Patients often spend less time in the hospital. Recovery is also faster, with fewer risks. Doctors prefer DEBs because they reduce long-term complications. This shift is especially useful for older patients or those with other health issues. As hospitals look to improve care while lowering costs, DEBs fit well into modern treatment plans.

3. Increased Research in Coronary Artery Disease Applications

While DEBs are mostly used in peripheral arteries, research is now expanding into coronary artery disease. This condition affects blood vessels in the heart. Some patients, especially those with small or hard-to-reach vessels, may not be good candidates for stents. In these cases, DEBs are showing promising results. Clinical trials are ongoing to test their safety and long-term effectiveness in coronary use. If these studies succeed, DEBs could be approved for more heart-related procedures. This opens up new markets and offers new options for patients with complex heart issues.

4. Rise in Diabetic and Aging Populations

The global rise in diabetes and aging is increasing demand for better vascular treatments. Diabetic patients often have narrower or more delicate arteries. Traditional stents may not always work well for them. DEBs provide a safer, drug-based approach without leaving a permanent implant. Older adults also benefit from the low-risk nature of DEBs. With longer life expectancy and higher rates of chronic illness, more people need reliable vascular care. This growing patient base is driving demand for drug eluting balloons. Healthcare providers are noticing this trend and adopting DEBs for more cases.

5. Advancements in Drug Coating Technologies

New drug coating technologies are making DEBs more effective. These coatings help the drug stay longer in the artery and release more slowly. This improves treatment results and lowers the risk of complications. Researchers are developing better materials that stick well to the balloon and deliver the drug evenly. These improvements are boosting the performance and trust in DEBs. Better coatings also mean DEBs can be used in more complex procedures. As technology advances, patients and doctors are seeing better outcomes. This is helping expand the use of DEBs in vascular care.

6. Government Support and Health Policy Changes

Governments and health organizations are backing non-stent-based treatments like DEBs. Many countries are updating their clinical guidelines to include DEBs as a recommended option. Public hospitals are getting funding to adopt this technology. Some national health insurance programs now cover DEB procedures. This support makes DEBs more accessible, especially in developing countries. With lower costs and improved outcomes, DEBs are gaining approval from policymakers. These policy changes are helping drive wider use. As more healthcare systems adopt DEBs, their role in vascular treatment will continue to grow.

Conclusion

In conclusion, the drug eluting balloon market is showing strong and steady growth due to the rising cases of heart and vascular diseases across the globe. With more people developing conditions like diabetes and peripheral artery disease, the demand for safer, non-invasive treatments is increasing. Drug eluting balloons are gaining popularity because they offer faster recovery and fewer complications than traditional methods. Healthcare systems are supporting this shift by updating treatment guidelines and funding access to DEB technologies. Continued advancements in drug coatings and expanded research are also helping the market grow. As awareness spreads and more hospitals adopt this solution, DEBs are becoming a key part of modern vascular care.